Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients. METHODS Evidence-based review. RESULTS Statin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-high-risk patients with mild to moderately elevated TG levels (>2.3 and < 5.6 mmol/L [>200 and < 500 mg/dL) on a statin, treatment with either a fibrate or high-dose omega-3 fatty acids (icosapent ethyl) may be considered, weighing the benefit versus risks. Combination with fenofibrate may be considered for both macro- and microvascular benefits in patients with type 2 diabetes mellitus. CONCLUSIONS This guidance aims to improve real-world use of guideline-recommended combination lipid modifying treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Self-citationFerence, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationEstruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800389 · Cited by 3,616
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Research works printed but not linked: 50
- Béliard, 2018, High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: the French Familial Hypercholesterolemia Registry, Atherosclerosis, 277, 334, 10.1016/j.atherosclerosis.2018.08.010 · DOI
- Vrablik, 2018, Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: results of the PLANET registry, Atherosclerosis, 277, 355, 10.1016/j.atherosclerosis.2018.08.008 · DOI
- Ray, 2020, DA VINCI study, EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study, Eur J Prev Cardiol
- Kotseva, 2019, Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry, Eur J Prev Cardiol, 26, 824, 10.1177/2047487318825350 · DOI · Paper page
- De Backer, 2019, Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries, Atherosclerosis, 285, 135, 10.1016/j.atherosclerosis.2019.03.014 · DOI · Paper page
- Gencer, 2015, Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes, Atherosclerosis, 239, 118, 10.1016/j.atherosclerosis.2014.12.049 · DOI
- Gencer, 2020, Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: a contemporary analysis from the SPUM-ACS cohort, Int. J. Cardiol., 303, 8, 10.1016/j.ijcard.2019.12.011 · DOI
- Drexel, 2020, An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: barriers to be overcome, Eur Heart J Cardiovasct Pharmacother, 6, 115, 10.1093/ehjcvp/pvz079 · DOI
- Penson, 2020, LDL-C: lower is better for longer-even at low risk, BMC Med., 18, 320, 10.1186/s12916-020-01792-7 · DOI · Paper page
- Lauridsen, 2015, Genetic variation in the cholesterol transporter NPC1L1, ischemic vascular disease and gallstone disease, Eur. Heart J., 36, 1601, 10.1093/eurheartj/ehv108 · DOI · Paper page
- Ference, 2019, Mendelian randomization study of ACLY and cardiovascular disease, N. Engl. J. Med., 380, 1033, 10.1056/NEJMoa1806747 · DOI · Paper page
- Bacquer, 2019, Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: real world evidence from clinical practice: data from the ESC-EORP EUROASPIRE V Study, Eur J Prev Cardiol
- Schiele, 2017, Coronary artery disease: risk stratification and patient selection for more aggressive secondary prevention, Eur J Prev Cardiol, 24, 88, 10.1177/2047487317706586 · DOI
- Dyrbus, 2020, Lipid disorders therapy in patients with chronic coronary syndrome and myocardial infarction. Experts opinion of the polish society of Cardiology (PCS) and the polish lipid associatin (PoLA), Kardiol. Pol.
- Amarenco, 2020, Treat Stroke to Target Investigators. A comparison of two LDL cholesterol targets after ischemic stroke, N. Engl. J. Med., 382, 9, 10.1056/NEJMoa1910355 · DOI · Paper page
- Ballantyne, 2019, Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy, Eur J Prev Cardiol
- Annemans, 2018, 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies, Eur. Heart J., 39, 2546, 10.1093/eurheartj/ehx710 · DOI · Paper page
- Carnicelli, 2020, In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG, Ann. Intern. Med., 172, 10.7326/ACPJ202001210-003 · doi:10.7326/acpj202001210-003
- Goodman, 2019, Effects of alirocumab on cardiovascular events after coronary bypass surgery, J. Am. Coll. Cardiol., 74, 1177, 10.1016/j.jacc.2019.07.015 · DOI
- Diaz, 2020, ODYSSEY OUTCOMES Committees and Investigators. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial, Eur J Prev Cardiol
- Jukema, 2019, Effect of alirocumab on stroke in ODYSSEY OUTCOMES, Circulation, 140, 2054, 10.1161/CIRCULATIONAHA.119.043826 · DOI · Paper page
- Santos, 2020, Long-term evolocumab in patients with familial hypercholesterolemia, J. Am. Coll. Cardiol., 75, 565, 10.1016/j.jacc.2019.12.020 · DOI · Paper page
- Dufour, 2019, Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: results from an open-label extension of the ODYSSEY LONG TERM trial, J Clin Lipidol, 13, 138, 10.1016/j.jacl.2018.11.007 · DOI
- Dressel, 2019, Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: insights from the Ludwigshafen Risk and Cardiovascular Health cohort, Vasc. Pharmacol., 120, 106566, 10.1016/j.vph.2019.106566 · DOI
- Banach, 2020, Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia, JAMA Cardiol, 5, 1, 10.1001/jamacardio.2020.2314 · DOI · Paper page
- Alder, 2020, A meta-analysis assessing additional LDL-C reduction from addition of a bile acid sequestrant to statin therapy, Am. J. Med., S0002–9343, 30372
- Handelsman, 2011, Role of bile acid sequestrants in the treatment of type 2 diabetes, Diabetes Care, 34, S244, 10.2337/dc11-s237 · DOI · Paper page
- Sabatine, 2018, Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis, JAMA Cardiol, 3, 823, 10.1001/jamacardio.2018.2258 · DOI · Paper page
- Koren, 2019, Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia, J. Am. Coll. Cardiol., 74, 2132, 10.1016/j.jacc.2019.08.1024 · DOI · Paper page
- Gürgöze, 2019, Adverse events associated with PCSK9 inhibitors: a real-world experience, Clin. Pharmacol. Ther., 105, 496, 10.1002/cpt.1193 · DOI · Paper page
- Nordestgaard, 2013, Eur. Heart J., 34, 3478, 10.1093/eurheartj/eht273 · DOI · Paper page
- Schmidt, 2018, Atherosclerosis, 277, 314, 10.1016/j.atherosclerosis.2018.08.050 · DOI
- Baum, 2019, Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: results of the randomized, controlled, open label DE LAVAL study, J Clin Lipidol, 13, 901, 10.1016/j.jacl.2019.10.003 · DOI
- Moriarty, 2016, Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial, Eur. Heart J., 37, 3588, 10.1093/eurheartj/ehw388 · DOI · Paper page
- Cicero, 2017, Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel, Nutr. Rev., 75, 731, 10.1093/nutrit/nux047 · DOI · Paper page
- Cofán, 2019, Use of plant sterol and stanol fortified foods in clinical practice, Curr. Med. Chem., 26, 6691, 10.2174/0929867325666180709114524 · DOI
- Penson, 2020, The role of nutraceuticals in the optimization of lipid-lowering therapy in high-risk patients with dyslipidaemia, Curr. Atherosclerosis Rep., 22, 67, 10.1007/s11883-020-00887-z · DOI
- Aggett, 2018, Scientific opinion on the safety of monacolins in red yeast rice, EFSA Journal
- Banach, 2019, The role of red yeast rice (RYR) supplementation in plasma cholesterol control: a review and expert opinion, Atherosclerosis Suppl., 39, e1, 10.1016/j.atherosclerosissup.2019.08.023 · DOI
- Fogacci, 2019, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group; International Lipid Expert Panel (ILEP). Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials, Pharmacol. Res., 143, 1, 10.1016/j.phrs.2019.02.028 · DOI · Paper page
- 2017, Reiner Ž Hypertriglyceridaemia and risk of coronary artery disease, Nat. Rev. Cardiol., 14, 401, 10.1038/nrcardio.2017.31 · DOI · Paper page
- Penson, 2019, Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study, Cardiovasc. Res., 115, 204, 10.1093/cvr/cvy198 · DOI
- Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
- Ginsberg, 2011, The ACCORD (action to control cardiovascular risk in diabetes) lipid trial: what we learn from subgroup analyses, Diabetes Care, 34, S107, 10.2337/dc11-s203 · DOI · Paper page
- Bernelot Moens, 2017, Remnant cholesterol elicits arterial wall inflammation and a multilevel cellular immune response in humans, Arterioscler. Thromb. Vasc. Biol., 37, 969, 10.1161/ATVBAHA.116.308834 · DOI · Paper page
- Norata, 2007, Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies, Atherosclerosis, 193, 321, 10.1016/j.atherosclerosis.2006.09.015 · DOI
- Sacks, 2014, Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries, Circulation, 129, 999, 10.1161/CIRCULATIONAHA.113.002529 · DOI · Paper page
- Sharma, 2020, Effects of omega-3 fatty acids on major adverse cardiovascular events: what matters most: the drug, the dose, or the placebo?, J. Am. Med. Assoc., 10.1001/jama.2020.22387 · DOI
- Keech, 2007, FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial, Lancet, 370, 1687, 10.1016/S0140-6736(07)61607-9 · DOI · Paper page
- Catapano, 2020, Insights from ORION studies: focus on inclisiran safety, Cardiovasc. Res.
Cited by
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
Ray, K. K., Haq, I., Bilitou, A., Manu, M. C., Burden, A., Aguiar, C., Arca, M., Connolly, D. L., Eriksson, M., Ferrières, J., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100624 · Cited by 339
Self-citationWang, T., Zhang, X., Zhou, N., Shen, Y., Li, B., Chen, B. E., & Li, X. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029512 · Cited by 73
Mach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.07.001 · Cited by 57
Self-citationDifferentiating EPA from EPA/DHA in cardiovascular risk reduction
Toth, P. P., Chapman, M. J., Parhofer, K. G., & Nelson, J. R. (2022) · American Heart Journal Plus: Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100148 · Cited by 33
Metadata
- Authors
- Averna, M., Banach, M., Bruckert, E., Drexel, H., Farnier, M., Gaita, D., Magni, P., März, W., Masana, L., Mello e Silva, A., Reiner, Z., Ros, E., Vrablik, M., Zambon, A., Zamorano, J. L., Stock, J. K., Tokgözoğlu, L. S., & Catapano, A. L.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 325
- Pages
- 99-109
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W3153390842
- Cited by
- 137
- References
- 63
- FWCI
- 22.45
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Instituto de Salud Carlos III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2021.03.039
- The paper
- Averna, M., Banach, M., Bruckert, E., Drexel, H., Farnier, M., Gaita, D., Magni, P., März, W., Masana, L., Mello e Silva, A., Reiner, Z., Ros, E., Vrablik, M., Zambon, A., Zamorano, J. L., Stock, J. K., Tokgözoğlu, L. S., & Catapano, A. L. (2021). Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2021.03.039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.